Shares in Prosensa Holding NV plunged 70.3 percent Friday on news that its exon-skipping antisense drug drisapersen failed to meet the primary endpoint of a Phase III trial in Duchenne muscular dystrophy (DMD).
Morphosys AG raised €84 million (US$114 million) in a private placement, adding another hefty chunk of change to what is already a robust balance sheet.
A consortium led by the Royal College of Surgeons in Ireland (RCSI) has secured €11.5 million (US$15.4 million) in funding from the European Commission (EC) to build a comprehensive picture of microRNA (miRNA) biology in patients with epilepsy.
The European Medicines Agency (EMA) is introducing a sweeping reorganization, which it hopes will lead to greater efficiency and effectiveness despite the budgetary constraints it is facing, as the European Union continues to battle through an economic crisis that has now lasted for half a decade.
The European Medicines Agency (EMA) is introducing a sweeping reorganization, which it hopes will lead to greater efficiency and effectiveness despite the budgetary constraints it is facing, as the European Union continues to battle through an economic crisis that has now lasted for half a decade.
With the start of a Phase III trial of its lead compound tinnitus drug AM-101 imminent, Auris Medical AG has completed a second Phase II trial, which further rounds out its understanding of how to administer the therapy.
Shares in Transgene SA dropped 13 percent last week on news that the oncolytic immunotherapy Pexa-Vec (JX-594, pexastimogene devacirepvec) failed to attain the primary endpoint of overall survival in a Phase IIb trial in 80 patients with advanced liver cancer.
Hospira Inc. has reached a major milestone in the development of the biosimilar drugs market by gaining formal European Commission approval for Europe’s first biosimilar monoclonal antibody, Inflectra (infliximab), which is based on the blockbuster TNF-alpha inhibitor Remicade (infliximab). It represents the first major dent in the armor of the biotechnology industry’s most valuable franchise.
Hospira Inc. has reached a major milestone in the development of the biosimilar drugs market by gaining formal European Commission approval for Europe’s first biosimilar monoclonal antibody, Inflectra (infliximab), which is based on the blockbuster TNF-alpha inhibitor Remicade (infliximab). It represents the first major dent in the armor of the biotechnology industry’s most valuable franchise.
With the start of a Phase III trial of its lead compound tinnitus drug AM-101 imminent, Auris Medical AG has completed a second Phase II trial, which further rounds out its understanding of how to administer the therapy.
